ClinicalTrials.gg
Not yet recruitingNCT07538271Aurora 005Updated Apr 20, 2026

A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer

A Phase 2 interventional study of benmelstobart and Anlotinib in SCLC, Extensive Stage, sponsored by Yayi He. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-20.

Sponsored by Yayi He · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing benmelstobart in Small Cell Lung Carcinoma — 8 open to participants now, 8 under way, 2 of them phase 3. benmelstobart · Small Cell Lung Carcinoma.

Planned enrollment
8th of 10
33 · median 45
Started
2026
with 2 others
Phase 2
5 of 10
4 open now
Registered
8th of 10
by date
Lead sponsor
2 of 10
Yayi He

Among the 10 studies testing benmelstobart in Small Cell Lung Carcinoma, this one is the 8th largest by planned enrollment, is one of 3 that started in 2026, is one of 5 in phase 2, and was the 8th registered.

Small Cell Lung Carcinoma

1,303 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

8 of the 10 studies testing benmelstobart in Small Cell Lung Carcinoma are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About benmelstobart

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 176 (66%) set no upper age limit and 65 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing benmelstobart in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

This is a single-center, single-arm, exploratory clinical study conducted at Shanghai Pulmonary Hospital, Tongji University. It aims to evaluate the efficacy and safety of first-line treatment with benmelstobart plus anlotinib and chemotherapy (carboplatin/cisplatin plus etoposide), followed by sequential thoracic radiotherapy, in patients with previously untreated extensive-stage small cell lung cancer (ES-SCLC).

Eligible participants will be adults aged 18-75 years with histologically or cytologically confirmed ES-SCLC, measurable lesions per RECIST 1.1, ECOG performance status 0-1, and adequate organ function. Patients will receive 4 cycles of induction therapy (benmelstobart, anlotinib, platinum-etoposide chemotherapy). Those without disease progression will receive consolidative thoracic radiotherapy, followed by maintenance therapy with benmelstobart plus anlotinib until disease progression or unacceptable toxicity.

The primary endpoint is objective response rate (ORR) assessed by investigators. Secondary endpoints include progression-free survival (PFS), overall survival (OS), disease control rate (DCR), duration of response (DOR), and safety parameters including adverse events graded by CTCAE 5.0. A total of 33 subjects will be enrolled. This study uses a non-randomized, open-label design without a control group.

Read the detailed description

This is a single-center, single-arm, prospective, exploratory clinical trial to evaluate the efficacy and safety of first-line benmelstobart combined with anlotinib and platinum-etoposide chemotherapy, followed by sequential thoracic radiotherapy, in patients with untreated extensive-stage small cell lung cancer (ES-SCLC).

Eligible patients will receive 4 cycles of 21-day induction therapy consisting of intravenous benmelstobart 1200 mg on day 1, oral anlotinib 12 mg once daily for 2 weeks on / 1 week off, plus carboplatin (AUC 5) or cisplatin (75-80 mg/m²) on day 1 and etoposide 100 mg/m² on days 1-3 of each cycle. Patients without disease progression after induction therapy will receive consolidative thoracic radiotherapy (2 Gy per fraction, 25-30 fractions). Maintenance therapy with benmelstobart plus anlotinib will be administered until disease progression, unacceptable toxicity, or a maximum of 2 years.

The primary outcome is investigator-assessed objective response rate (ORR) per RECIST 1.1. Secondary outcomes include progression-free survival (PFS), overall survival (OS), disease control rate (DCR), duration of response (DOR), and safety assessed by adverse events (AE, SAE, irAE) graded according to CTCAE version 5.0. A total of 33 subjects will be enrolled.

03

Conditions studied

  • SCLC, Extensive Stage

Keywords

  • Small Cell Lung Cancer
  • Extensive-Stage
  • Benmelstobart
  • Anlotinib
  • Chemotherapy
  • Thoracic Radiotherapy
  • First-Line
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1: or cytologically confirmed inoperable extensive-stage small cell lung cancer (ES-SCLC) according to the VALG staging system

    2: No prior systemic therapy for extensive-stage small cell lung cancer (ES-SCLC)

    3: Presence of as defined by the 1.1 criteria. A previously irradiated lesion can be considered measurable only if there is clear progression after radiotherapy and it is not the sole lesion

    4: Aged 18 to 75 years

    5: performance status score of 0 to 1

    6: Expected survival time ≥ 3 months

    7: Number of tumor ≤ 3. must be asymptomatic or treated and stable for at least 1 month prior to the initiation of study treatment, with no use of or anticonvulsants during this period

    8: Adequate hematological and organ function, meeting the following criteria: a) Hematology (no blood transfusion or blood products within 14 days; no correction with G-CSF or other hematopoietic stimulants): i. (ANC) ≥ 1.5 × 10⁹/L (1,500/mm³); ii. Count (PLT) ≥ 100 × 10⁹/L (100,000/mm³); iii. (HB) ≥ 80 g/L. b) Renal function: i. Calculated Rate (CrCl) ≥ 50 mL/min; ii. Urine protein \< 2+ or 24-hour urinary protein quantitation \< 1.0 g. c) Hepatic function: i. Serum Total (TBil) ≤ 1.5 × (for patients with liver metastases, TBil ≤ 3 × ULN); ii. and ALT ≤ 2.5 × ULN (for patients with liver metastases, ≤ 5 × ULN); iii. Serum Albumin (ALB) ≥ 28 g/L. d) Coagulation function: i. (INR) and Activated Partial Thromboplastin Time (APTT) ≤ 1.5 × ULN. e) Cardiac function: i. (LVEF) ≥ 50%. f) Other: i. Lipase ≤ 1.5 × ULN; patients with lipase > 1.5 × ULN may be enrolled if there is no clinical or radiological evidence of pancreatitis; ii. Amylase ≤ 1.5 × ULN; patients with amylase > 1.5 × ULN may be enrolled if there is no clinical or radiological evidence of pancreatitis; iii. Alkaline Phosphatase (ALP) ≤ 2.5 × ULN (for patients with bone metastases, ALP ≤ 5 × ULN

    9: The subject voluntarily agrees to participate in the study, signs the form, has good compliance, and is willing to cooperate with follow-up

Exclusion criteria

Exclusion Criteria:

  • 1: Patients with symptomatic . Patients whose brain metastases have been treated and remain clinically stable for at least 1 month, with no use of or anticonvulsants for at least 1 month prior to study enrollment, are eligible

    2: Prior use of anti-angiogenic agents such as anlotinib, apatinib, bevacizumab, or targeting PD-1, PD-L1, etc

    3: Patients with conditions that affect oral drug administration (e.g., dysphagia, post-gastrointestinal resection, chronic diarrhea, intestinal obstruction, etc.)

    4: Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage

    5: Patients with radiological evidence of tumor invasion around major blood vessels, or those judged by the investigator to be at high risk of fatal massive hemorrhage due to potential tumor invasion of major blood vessels during the study

    6: History of severe bleeding tendency or coagulation disorders, including but not limited to: hemoptysis (≥ 1 tablespoon per day) within 3 months prior to enrollment; or clinically significant bleeding symptoms or tendency within 4 weeks prior to group assignment, such as gastrointestinal bleeding, hemorrhagic gastric ulcer (including gastrointestinal perforation and/or fistula; patients with gastrointestinal perforation or fistula that has been surgically resected are eligible), unhealed wounds, ulcers, or fractures, etc

    7: Receipt of major surgical treatment, incisional , or significant traumatic injury within 28 days prior to group assignment

    8: History of arterial/venous thrombotic events (e.g., cerebrovascular accident including , deep vein thrombosis, pulmonary embolism) within 6 months prior to group assignment

    9: Active disease requiring systemic treatment (e.g., disease-modifying antirheumatic drugs, corticosteroids, or ) within 2 years prior to the first dose of study drug

    10: Other conditions that increase the risk associated with study participation or study drugs and, in the investigator's judgment, render the patient unsuitable for enrollment

Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (estimated)

Study arms

  • Experimental
    Benmelstobart + Anlotinib + Chemotherapy Followed by Thoracic Radiotherapy

    Eligible patients receive 4 cycles of induction therapy (benmelstobart 1200mg IV D1 + anlotinib 12mg PO QD 2w-on/1w-off + carboplatin/cisplatin + etoposide). Non-progressive patients proceed to consolidative thoracic radiotherapy (2Gy/fraction, 25-30 fractions), followed by maintenance therapy with benmelstobart + anlotinib until disease progression or unacceptable toxicity.

    Drug: benmelstobart · Drug: Anlotinib · Drug: Carboplatin or cisplatin · Drug: Etoposide · Radiation: Thoracic Radiotherapy

Interventions

  • A PD-L1 inhibitor (biological product) administered intravenously. Used for immunotherapy in combination with other agents to treat extensive-stage small cell lung cancer (ES-SCLC).

  • A small-molecule anti-angiogenic drug administered orally. Inhibits tumor angiogenesis to suppress tumor growth, used as part of the first-line combined therapy for ES-SCLC.

  • DrugCarboplatin or cisplatin

    Drug pages: CarboplatinStudies of CarboplatinCarboplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CisplatinStudies of CisplatinCisplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A platinum-based chemotherapeutic agent administered intravenously.

  • A topoisomerase II inhibitor administered intravenously. Works by interfering with tumor cell replication, combined with platinum agents as first-line chemotherapy for ES-SCLC.

  • RadiationThoracic Radiotherapy

    External beam radiation therapy delivered to the thoracic region. Administered as consolidative treatment for non-progressive ES-SCLC patients after induction therapy, with a total dose based on clinical practice guidelines.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Investigator-assessed ORR per RECIST 1.1 in ES-SCLC patients treated with benmelstobart plus anlotinib and chemotherapy followed by thoracic radiotherapy.

    Time frame: Baseline at screening, after every 2 treatment cycles (each cycle is 21 days), end of treatment, up to disease progression, assessed up to approximately 24 months

Secondary outcomes

  1. Progression-Free Survival (PFS)

    Time from first treatment to disease progression or death from any cause, whichever occurs first

    Time frame: Date of first study treatment to date of disease progression or death from any cause, last follow-up, assessed up to approximately 24 months

  2. Overall Survival (OS)

    Time from first study treatment to death from any cause; censored at last follow-up for alive subjects

    Time frame: From date of first study treatment to date of death from any cause or last follow-up, whichever occurs first, assessed up to approximately 24 months

  3. 6-Month Progression-Free Survival Rate

    Estimated proportion of subjects without progression and alive at 6 months after first treatment using Kaplan-Meier method

    Time frame: 6-month time point after first treatment, follow-up cutoff

  4. Serious Adverse Event (SAE)

    Collect SAEs resulting in death, life-threatening condition, hospitalization, disability per CTCAE 5.0 and ICH-GCP, document and report

    Time frame: from date of first study drug administration , follow-up until resolution or stabilization, assessed up to approximately 24 months

  5. Adverse Event (AE)

    Record all new or worsening unfavorable medical events, grade and calculate incidence according to CTCAE 5.0

    Time frame: From signing informed consent through study completion and safety follow-up, assessed up to approximately 24 months

  6. 18-Month Overall Survival Rate

    Estimated proportion of alive subjects at 18 months after first treatment via Kaplan-Meier method

    Time frame: 18-month time point after first treatment, follow-up cutoff

  7. Duration of Response (DOR)

    Time from first confirmed CR/PR to disease progression, death from any cause, or initiation of new antitumor therapy

    Time frame: From date of first confirmed objective response (CR/PR) until date of disease progression, death from any cause, or initiation of new antitumor therapy, whichever occurs first, assessed up to approximately 24 months

  8. 12-Month Progression-Free Survival Rate

    Estimated proportion of progression-free and alive subjects at 12 months via Kaplan-Meier method

    Time frame: 12-month time point after first treatment, follow-up cutoff

  9. 12-Month Overall Survival Rate

    Estimated proportion of alive subjects at 12 months after first treatment using Kaplan-Meier method

    Time frame: 12-month time point after first treatment, follow-up cutoff

  10. Disease Control Rate (DCR)

    According to RECIST 1.1, proportion of subjects achieving CR, PR, or stable disease (SD) in total enrolled population

    Time frame: Time Frame: Baseline and after every 2 treatment cycles (each cycle is 21 days), up to disease progression, death, or study withdrawal, whichever occurs first,assessed up to approximately 24 months

  11. Immune-Related Adverse Event (irAE)

    Identify and grade organ-specific immune-related adverse events according to CTCAE 5.0 and irAE criteria

    Time frame: From date of first study drug administration through 90 days after the last dose of study drug; assessed at baseline, each cycle visit, and unscheduled visits for suspected irAEs; graded per CTCAE 5.0 and irAE-specific criteria.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided — IPD sharing plans are currently undecided given the exploratory nature of this single-center study. Further assessment will be conducted based on study completion, data quality verification, and ethical considerations (e.g., participant privacy protection). A detailed sharing protocol will be finalized and disclosed as appropriate.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Sep 2027, 17 months later.

Of 150 non-industry phase 2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 87. This study's planned 17 months is below that.

Counting every sponsor, half of 204 studies reached it within 46 months; a quarter within 29 and three quarters within 84.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2026
First posted
Apr 20, 2026
StartEst.
Apr 20, 2026
Primary completionEst.
Sep 30, 2027
CompletionEst.
Mar 31, 2029
Last update
Apr 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07538271
Lead sponsor
Yayi He
Responsible party
Yayi He (Professor, Shanghai Pulmonary Hospital, Shanghai, China) — Sponsor-investigator
First posted
Apr 20, 2026
Start date
Apr 20, 2026 (estimated)
Primary completion
Sep 30, 2027 (estimated)
Completion
Mar 31, 2029 (estimated)
Last update
Apr 20, 2026

Study contacts

Yayi He, MD
Contact
yayi.he@tongji.edu.cn
021-65115006-2393

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Benmelstobart · Anlotinib

Start the discussion